Versant Venture Management, LLC Long-Term Concentrated

Location: San Francisco, CA

CIK: 0001560009 · Show all filings

Period: Q1 2024 (← Previous) (Next →)

Filing Date: May 3, 2024

Total Value: $103M (100.0% shares, 0.0% debt)

Holdings (7)

CRSP CRISPR Therapeutics AG 32.9%

Value $33.98M Shares 498,558 Est. Cost $40.26 Unrealized +77.8%

SKYE Skye Bioscience, Inc. 30.4%

Value $31.4M Shares 2,007,702 Est. Cost $7.75 Unrealized 0.0%

— Repare Therapeutics, Inc. 12.1%

Value $12.47M Shares 2,646,657 Est. Cost $10.58 Unrealized —

— Gritstone Oncology, Inc. 8.9%

Value $9.152M Shares 3,561,150 Est. Cost $7767.86 Unrealized —

— Adverum Biotechnologies, Inc. 6.9%

Value $7.166M Shares 506,822 Est. Cost $9646.10 Unrealized —

— Passage Bio, Inc. 6.5%

Value $6.696M Shares 4,959,769 Est. Cost $17.48 Unrealized —

— Aligos Therapeutics, Inc. 2.2%

Value $2.274M Shares 2,320,381 Est. Cost $27.65 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
CRSP	CRISPR Therapeutics AG	498,558	$33.98M	32.9%	$40.26	+77.8%	Common Stock	H17182108
SKYE	Skye Bioscience, Inc.	2,007,702	$31.4M	30.4%	$7.75	0.0%	Common Stock	83086J200
—	Repare Therapeutics, Inc.	2,646,657	$12.47M	12.1%	$10.58	—	Common Stock	760273102
—	Gritstone Oncology, Inc.	3,561,150	$9.152M	8.9%	$7767.86	—	Common Stock	39868T105
—	Adverum Biotechnologies, Inc.	506,822	$7.166M	6.9%	$9646.10	—	Common Stock	00773U108
—	Passage Bio, Inc.	4,959,769	$6.696M	6.5%	$17.48	—	Common Stock	702712100
—	Aligos Therapeutics, Inc.	2,320,381	$2.274M	2.2%	$27.65	—	Common Stock	01626L105